Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masahiko Hagihara is active.

Publication


Featured researches published by Masahiko Hagihara.


Bioorganic & Medicinal Chemistry Letters | 1999

Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: a new class of anti-HIV agents.

Masahiko Hagihara; Hiroto Kashiwase; Tetsushi Katsube; Tomio Kimura; Tomoaki Komai; Kenji Momota; Toshinori Ohmine; Takashi Nishigaki; Satoshi Kimura; Kaoru Shimada

Synthesis and anti-HIV activity of a series of novel arylpiperazinyl fluoroquinolones are reported. In the SAR study, the aryl substituents on the piperazine nitrogen were found to play an important role for the anti-HIV-1 activity. A few of the compounds exhibited potent anti-HIV activity: IC50=0.06 microM in chronically infected cells.


Bioorganic & Medicinal Chemistry Letters | 2002

Anti-HIV-1 Activities and Pharmacokinetics of New Arylpiperazinyl Fluoroquinolones

Toshinori Ohmine; Tetsushi Katsube; Yasunori Tsuzaki; Miho Kazui; Nobuhiro Kobayashi; Tomoaki Komai; Masahiko Hagihara; Takashi Nishigaki; Aikichi Iwamoto; Tomio Kimura; Hiroto Kashiwase; Makoto Yamashita

Anti-HIV-1 activities and pharmacokinetics of a series of novel arylpiperazinyl fluoroquinolones are reported. Modification at the C-8 position with a trifluoromethyl group was superior to that with a difluoromethoxy group to achieve higher anti-HIV-1 activity. Two compounds studied exhibited quite high anti-HIV-1 activities (IC(50)<50 nM) in vitro and high bioavailabilities (BA>90%) in monkeys.


Journal of Biological Chemistry | 2012

Mechanism for p38α-mediated experimental autoimmune encephalomyelitis

Kana Namiki; Hirofumi Matsunaga; Kento Yoshioka; Kensuke Tanaka; Kazuya Murata; Junji Ishida; Akira Sakairi; Jun-Dal Kim; Naoki Tokuhara; Nobuhiko Shibakawa; Motohisa Shimizu; Yukinori Wada; Yasunori Tokunaga; Manabu Shigetomi; Masahiko Hagihara; Sadao Kimura; Tatsuhiko Sudo; Akiyoshi Fukamizu; Yoshitoshi Kasuya

Background: p38 signaling pathway plays a key role in inflammatory diseases. Results: A single copy disruption of the p38α gene or a p38α inhibitor markedly reduced the pathogenesis of EAE by decreasing IL-17 production. Conclusion: p38α regulates the pathogenesis of EAE through transcriptional regulation of IL-17 production. Significance: Anti-p38α strategy achieves therapeutic benefit for the treatment of multiple sclerosis. One of the mitogen-activated protein kinases, p38, has been found to play a crucial role in various inflammatory responses. In this study, we analyzed the roles of p38α in multiple sclerosis, using an animal model, experimental autoimmune encephalomyelitis (EAE). p38α+/− mice (p38α−/− showed embryonic lethality) showed less severe neurological signs than WT mice. Adoptive transfer of lymph node cells (LNC) from sensitized WT mice with MOG(35–55) to naive WT-induced EAE was much more severe compared with the case using LNC from sensitized p38α+/− mice. Comprehensive analysis of cytokines from MOG(35–55)-challenged LNC by Western blot array revealed that production of IL-17 was significantly reduced by a single copy disruption of the p38α gene or a p38 inhibitor. Likewise, by a luciferase reporter assay, an electrophoresis mobility shift assay, and characterization of the relationship between p38 activity and IL-17 mRNA expression, we confirmed that p38 positively regulates transcription of the Il17 gene. Furthermore, oral administration of a highly specific p38α inhibitor (UR-5269) to WT mice at the onset of EAE markedly suppressed the progression of EAE compared with a vehicle group. These results suggest that p38α participates in the pathogenesis of EAE through IL-17 induction.


Laboratory Investigation | 2014

Therapeutic effect of lung mixed culture-derived epithelial cells on lung fibrosis

Kensuke Tanaka; Tetsuo Fujita; Hiroki Umezawa; Kana Namiki; Kento Yoshioka; Masahiko Hagihara; Tatsuhiko Sudo; Sadao Kimura; Koichiro Tatsumi; Yoshitoshi Kasuya

Cell-based therapy is recognized as one of potential therapeutic options for lung fibrosis. However, preparing stem/progenitor cells is complicated and not always efficient. Here, we show easily prepared cell populations having therapeutic capacity for lung inflammatory disease that are named as ‘lung mixed culture-derived epithelial cells’ (LMDECs). LMDECs expressed surfactant protein (SP)-C and gave rise to type I alveolar epithelial cells (AECs) in vitro and in vivo that partly satisfied type II AEC-like characteristics. An intratracheal delivery of not HEK 293 cells but LMDECs to the lung ameliorated bleomycin (BLM)-induced lung injury. A comprehensive analysis of bronchoalveolar fluid by western blot array revealed that LMDEC engraftment could improve the microenvironment in the BLM-instilled lung in association with stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 signaling axis. SDF-1 enhanced both migration activity and differentiating efficiency of LMDECs. Further classification of LMDECs by flow cytometric study showed that a major population of LMDECs (LMDECMaj, 84% of total LMDECs) was simultaneously SP-C+, CD44+, CD45+, and hematopoietic cell lineage+ and that LMDECs included bronchioalveolar stem cells (BASCs) showing SP-C+Clara cell secretory protein+stem cell antigen (Sca)1+ as a small population (1.8% of total LMDECs). CD44+-sorted LMDECMaj and Sca1+-sorted LMDECs equally ameliorated fibrosis induced by BLM like LMDECs did. However, infiltrated neutrophils were observed in Sca1+-sorted LMDEC-treated alveoli that was not typical in LMDECMaj- or LMDEC-treated alveoli. These findings suggest that the protective effect of LMDECs against BLM-induced lung injury depends greatly on that of LMDECMaj. Furthermore, the cells expressing both alveolar epithelial and hematopoietic cell lineage markers (SP-C+CD45+) that have characteristics corresponding to LMDECMaj were observed in the alveoli of lung and increased approximately threefold in response to BLM instillation. Taken together, LMDECs newly classified in the present study are easily culture expanded and have a potential role in future regenerative cell therapy for pulmonary fibrosis.


Frontiers in Pharmacology | 2017

Genetic and Pharmacological Inhibition of p38α Improves Locomotor Recovery after Spinal Cord Injury

Hiroki Umezawa; Yusuke Naito; Kensuke Tanaka; Kento Yoshioka; Kenichi Suzuki; Tatsuhiko Sudo; Masahiko Hagihara; Masahiko Hatano; Koichiro Tatsumi; Yoshitoshi Kasuya

One of the mitogen-activated protein kinases, p38α plays a crucial role in various inflammatory diseases and apoptosis of various types of cells. In this study, we investigated the pathophysiological roles of p38α in spinal cord injury (SCI), using a mouse model. Lateral hemisection at T9 of the SC was performed in wild type (WT) and p38α+/- mice (p38α-/- showed embryonic lethality). p38α+/- mice showed a better functional recovery from SCI-associated paralyzed hindlimbs compared to WT mice at 7 days post-injury (dpi), which remained until 28 dpi (an end time point of monitoring the behavior). In histopathological analysis at 28 dpi, there was more axonal regeneration with remyelination on the caudal side of the lesion epicenter in p38α+/- mice than in WT mice. At 7 dpi, infiltration of inflammatory cells into the lesion and expression of cytokines in the lesion were reduced in p38α+/- mice compared with WT mice. At the same time point, the number of apoptotic oligodendrocytes in the white matter at the caudal boarder of the lesion of p38α+/- mice was lower than that of WT mice. At 14 dpi, more neural and oligodendrocyte precursor cells in the gray matter and white matter, respectively, were observed around the lesion epicenter of p38α+/- mice compared with the case of WT mice. At the same time point, astrocytic scar formation was less apparent in p38α+/- than in WT mice, while compaction of inflammatory immune cells associated with the wound contraction was more apparent in p38α+/- than in WT mice. Furthermore, we verified the effectiveness of oral administration of SB239063, a p38α inhibitor on the hindlimb locomotor recovery after SCI. These results suggest that p38α deeply contributes to the pathogenesis of SCI and that inhibition of p38α is a beneficial strategy to recovery from SCI.


Archive | 2004

Novel indazole derivatives

Masahiko Hagihara; Ken-Ichi Komori; Hidetoshi Sunamoto; Hiroshi Nishida; Takeshi Matsugi; Tadashi Nakajima; Masakazu Hatano; Kazutaka Kido; Hideaki Hara


Archive | 2017

Process for producing high-purity prasugrel hydrochloride

Teruhiko Inoue; Kazuyoshi Nakamura; Masahiko Hagihara; Hiroyuki Miyata; Yukinori Wada; Naoyuki Yokota


Archive | 2007

Process for producing high-purity prasugrel and acid addition salt thereof

Teruhiko Inoue; Kazuyoshi Nakamura; Masahiko Hagihara; Hiroyuki Miyata; Yukinori Wada; Naoyuki Yokota


Archive | 2010

Pharmaceutical composition for treating or preventing glaucoma

Masahiko Hagihara; Kenji Yoneda; Eiji Okanari; Manabu Shigetomi


Archive | 2004

Novel olefin derivative

Masahiko Hagihara; Naoyuki Izumi; Yasunori Tsuzaki; Takeshi Matsugi; Tadashi Nakajima; Masakazu Hatano; Hideaki Hara

Collaboration


Dive into the Masahiko Hagihara's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takeshi Matsugi

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge